Chemours™

Chemours 2Q 2022 Earnings Presentation

July 28, 2022

Safe Harbor Statement and Other Matters

This presentation contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words "believe," "expect," "will," "anticipate," "plan," "estimate," "target," "project" and similar expressions, among others, generally identify "forward-looking statements," which speak only as of the date such statements were made. These forward-looking statements may address, among other things, the outcome or resolution of any pending or future environmental liabilities, the commencement, outcome or resolution of any regulatory inquiry, investigation or proceeding, the initiation, outcome or settlement of any litigation, changes in environmental regulations in the U.S. or other jurisdictions that affect demand for or adoption of our products, anticipated future operating and financial performance for our segments individually and our company as a whole, business plans, prospects, targets, goals and commitments, capital investments and projects and target capital expenditures, plans for dividends or share repurchases, sufficiency or longevity of intellectual property protection, cost reductions or savings targets, plans to increase profitability and growth, our ability to make acquisitions, integrate acquired businesses or assets into our operations, and achieve anticipated synergies or cost savings, all of which are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements are based on certain assumptions and expectations of future events that may not be accurate or realized. These statements are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties that are beyond Chemours' control. In addition, the current COVID-19 pandemic has significantly impacted the national and global economy and commodity and financial markets, which has had and we expect will continue to have a negative impact on our financial results. The full extent and impact of the pandemic is still being determined and to date has included significant volatility in financial and commodity markets and a severe disruption in economic activity. The public and private sector response has led to travel restrictions, temporary business closures, quarantines, stock market volatility, and interruptions in consumer and commercial activity globally. Matters outside our control have affected our business and operations and may or may continue to hinder our ability to provide goods and services to customers, cause disruptions in our supply chains, adversely affect our business partners, significantly reduce the demand for our products, adversely affect the health and welfare of our personnel or cause other unpredictable events. Additionally, there may be other risks and uncertainties that Chemours is unable to identify at this time or that Chemours does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include the risks, uncertainties and other factors discussed in our filings with the U.S. Securities and Exchange Commission, including in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 and in our Annual Report on Form 10-K for the year ended December 31, 2021. Chemours assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law.

We prepare our financial statements in accordance with Generally Accepted Accounting Principles (“GAAP”). Within this presentation we may make reference to Adjusted Net Income, Adjusted EPS, Adjusted EBITDA, Adjusted EBITDA Margin, Free Cash Flow, Adjusted Effective Tax Rate, Return on Invested Capital (ROIC) and Net Leverage Ratio which are non-GAAP financial measures. The company includes these non-GAAP financial measures because management believes they are useful to investors in that they provide for greater transparency with respect to supplemental information used by management in its financial and operational decision making. Further information with respect to and reconciliations of such measures to the nearest GAAP measure can be found in the appendix hereto.

Management uses Adjusted Net Income, Adjusted EPS, Adjusted EBITDA, Adjusted EBITDA Margin, Free Cash Flow, Adjusted Effective Tax Rate, ROIC and Net Leverage Ratio to evaluate the company’s performance excluding the impact of certain noncash charges and other special items which we expect to be infrequent in occurrence in order to have comparable financial results to analyze changes in our underlying business from quarter to quarter.

Additional information for investors is available on the company’s website at investors.chemours.com.

Second Quarter 2022 Highlights

Delivered strong 2Q results with record Net Sales, and Adjusted EBITDA growth of 30% y-o-y

Achieved TSS record Net Sales and Adjusted EBITDA, announced Opteon™ YF expansion

Achieved APM record Net Sales and Adjusted EBITDA, and margin for a second straight quarter

Delivered on commitments to our AVA customers in TT despite ore constraints

Guiding towards the high-end of Adjusted EBITDA range and raising FCF guide to >$600M; repurchased $272M of shares through 2Q

Advancing our Corporate Responsibility Commitment

Chemours 5th Corporate Responsibility Commitment Report Launches August 9

Sharing progress on advancing our sustainable portfolio, achieving emissions reductions, and driving investment in our communities

Our 2Q Momentum

- TT announces sustainability goals that advance Chemours' CRC objectives, as they aspire to be the most sustainable TiO_2 enterprise in the world
  - Reducing site energy intensity* by 20%; Implementing waste reduction technologies across all sites; 100% of all new offerings will include a sustainability value proposition; Lending expertise to solve societal challenges in TiO_2 and beyond
- Chemours leads Remove2Reclaim research initiative to recover TiO_2 and advance plastic circularity
- TSS continues to support customer transitions with Opteon™ low GWP thermal management solutions
- APM announces industry-leading sustainable process innovation to produce APA-grade Viton™ fluoroelastomers using a non-fluorinated surfactant
- Chemours receives EcoVadis gold certification – placing the company in the top 5% of companies assessed for sustainability management
- Chemours and North Carolina A&T University partner to advance STEM education and opportunities for students

versus a 2018 baseline

Investing in our shared planet through employee action on Earth Day.

Second Quarter 2022 Financial Summary

($ in millions unless otherwise noted)

	2Q22	2Q21	Δ Yr/Yr
Net Sales	$1,915	$1,655	*$260*
Net Income[1]	$201	$66	*$135*
Adj. Net Income	$302	$205	*$97*
EPS[2]	$1.26	$0.39	*$0.87*
Adj. EPS[3]	$1.89	$1.20	*$0.69*
Adj. EBITDA	$475	$366	*$109*
Adj. EBITDA Margin (%)[4]	25%	22%	*+300 bps*
Free Cash Flow[5]	$229	$189	*$40*
Pre-Tax ROIC (%)[6]	34%	20%	*+1,400 bps*

[1] Net Income attributable to The Chemours Company
[2] Calculation based on diluted share count
[3] Adjusted EPS excludes restructuring, gain/loss on sale, legal and environmental charges as well as other items – see Appendix for full details
[4] Defined as Adjusted EBITDA divided by Net Sales
[5] Defined as Cash from Operations minus cash used for PP&E purchases
[6] Defined as Adjusted EBITDA less depreciation & amortization on a trailing twelve-month basis divided by average invested capital over the last five quarters

Year-Over-Year

- Net Sales up 16% to a record $1.9 billion reflecting demand strength across the portfolio
- GAAP EPS of $1.26 up $0.87 and Adjusted EPS of $1.89 up $0.69[3]
- Adjusted EBITDA of $475 million up 30% y-o-y, driven by price outpacing raw material and logistics costs
- Margins improved to 25% vs. 22% in the prior-year, due to APM mix enrichment and strong demand for both legacy and low GWP refrigerants
- Free Cash Flow was $229 million, a 21% improvement vs. the prior-year

Chemours™

Adjusted EBITDA Bridge: 2Q22 versus 2Q21

($ in millions unless otherwise noted)



- Strong price gains driven by market dynamics in TSS, demand for high value, differentiated applications in APM, and TT value stabilization strategy
- FX was a (7)% headwind over the prior year quarter, primarily driven by USD strengthening
- Rising variable costs due to raw material cost inflation and supply chain issues
- Expect currency and rising variables costs to be headwinds in 2H

See reconciliation of Non-GAAP measures in the Appendix

Chemours™

Liquidity Position

($ in millions unless otherwise noted)

Gross debt	$3.7B
Net debt	$2.5B
TTM Net Leverage	1.6x



- Q2'22 ending cash balance of $1,248 million, up $103 million over prior-quarter
- Operating Cash Flow generation of $291 million
- Distributed $166 million of cash to shareholders - $128 million in share repurchases and $38 million of dividends
- Other of $40 million including the sale of non-operating assets – Beaumont and Pascagoula sites
- Total Liquidity of ~$2.0 billion[1]

See reconciliation of Non-GAAP measures in the Appendix

1 Including revolver availability of ~$0.8 billion, net of letters of credit

2 Excludes $2 million in repurchases that were executed but not settled until after June 30, 2022 close

3 Cash balances do not include $100 million of restricted cash which are part of Chemours' MOU commitments

Chemours™

On-site and Off-site Remediation at Fayetteville

($ in millions unless otherwise noted)

- $174 million in total charges related to legacy environmental remediation at Fayetteville were recorded in Q2 2022 of which $165 million was excluded from Adjusted EBITDA
- As of June 30, 2022, Chemours has reported a total liability of $510 million which reflects expected future cash outflows; approximately half of this amount is subject to cost-sharing with DuPont and Corteva under the terms of the MOU

Legacy environmental remediation at Fayetteville	Q2 2022 Charges			Remaining accruals (1)(3)
	Excl. from Adj. EBITDA	Incl. in Adj. EBITDA	Total	
On-site remediation	$57	$5	$62	$323
Off-site remediation	$108	$4	$112	$187
Total environmental remediation at Fayetteville	**$165**	**$9**	**$174**	**$510**

Illustrative Prospective Impact of Fayetteville Remediation Liabilities on Free Cash Flows(1)(2)



1) Environmental remediation liabilities primarily include costs related to on-site construction, off-site unit installations, and 20 years of operation, maintenance, and monitoring activities.

2) Amounts are subject to 50% cost-sharing with DuPont and Corteva under the MOU until the earlier to occur of: (i) December 31, 2040; (ii) the day on which the aggregate amount of Qualified Spend is equal to $4B; or, (iii) a termination in accordance with the terms of the MOU. Future cash outflows are presented sequentially and do not occur concurrently.

3) Reflects amounts remaining on the balance sheet as of June 30, 2022, of which $181 is classified as current and projected to be spent within the next 12 months.

Chemours™

Titanium Technologies Business Summary

Second Quarter Highlights

- Net Sales increased 13% to a record $968 million driven by a 23% contribution from price, partially offset by an (8%) decrease in volume and (2%) unfavorable currency movement
- Price improvements across the portfolio with 6% sequential increase essentially offsetting sequential input cost inflation
- Volume declined y-o-y and flat q-o-q due to continued ore constraints

Outlook

- Early signs of softer demand in Europe and China in certain grades and end-markets
- Anticipate robust portfolio of globally contracted customers to better support stabilization throughout the cycle
- Positioned to manage production to efficiently meet customers anticipated demand through all commercial channels despite ore constraints through 4Q

Second Quarter 2022 Financial Summary *($ in millions)*

Quarterly Net Sales



Sales Drivers

	Yr/Yr % Δ	Q/Q % Δ
Price	23	6
Volume	(8)	0
Currency	(2)	(2)

Quarterly Adjusted EBITDA



See reconciliation of Non-GAAP measures in the Appendix. Note that, beginning in 2022, the Company changed its methodology used to allocated certain corporate function expenses to the operating segments, and as such historical Adjusted EBITDA has been recast.

Thermal & Specialized Solutions Business Summary

Second Quarter Highlights

- Delivered 52% Net Sales growth driven by robust demand across the product portfolio and strong pricing despite currency headwinds
- Strong pricing driven by market and regulatory dynamics and our disciplined approach to offset higher raw material costs
- Adjusted EBITDA margin expanded 700 bps to 41% despite rising raw material, logistics and energy costs

Outlook

- Expect more typical (pre-covid) seasonality in the second half of the year
- Anticipate impact of higher raw material costs in the second half in comparison to same period last year
- Efforts underway to expand the capacity at our Corpus Christi facility in order to support customer needs for Opteon™ YF as they transition to low GWP solutions

Second Quarter 2022 Financial Summary *($ in millions)*

Quarterly Net Sales



Sales Drivers

	Yr/Yr % Δ	Q/Q % Δ
Price	39	1
Volume	15	21
Currency	(2)	0

Quarterly Adjusted EBITDA



See reconciliation of Non-GAAP measures in the Appendix. Note that, beginning in 2022, the Company changed its methodology used to allocated certain corporate function expenses to the operating segments, and as such historical Adjusted EBITDA has been recast.

Chemours™

Advanced Performance Materials Business Summary

Second Quarter Highlights

- Net Sales increased by 11% driven by continued demand strength in advanced electronics, semiconductors, and clean energy applications
- Price up 15% driven by demand outpacing supply in high value applications and actions to offset raw material inflation. Volume declined (1)% due to lower demand in non-strategic end markets
- Adjusted EBITDA up 35% and Adjusted EBITDA Margin increased 500 bps to 27%

Outlook

- Maintain focus on driving growth in end-markets with long-term secular trends in advanced electronics and clean energy including – semicon, H2, and electronics
- Anticipate value-based pricing and supply chain integration to help offset rising raw material and logistics costs
- Continue to execute strategy to optimize mix and target high value, differentiated offerings

Second Quarter 2022 Financial Summary *($ in millions)*

Quarterly Net Sales



Sales Drivers

	Yr/Yr % Δ	Q/Q % Δ
Price	15	2
Volume	(1)	4
Currency	(3)	(2)

Quarterly Adjusted EBITDA



See reconciliation of Non-GAAP measures in the Appendix. Note that, beginning in 2022, the Company changed its methodology used to allocated certain corporate function expenses to the operating segments, and as such historical Adjusted EBITDA has been recast.

Chemours™

Revised 2022 Guidance

Adjusted EBITDA

$1.475-$1.575 Billion

Current mid-point up 16% vs. from 2021 results

Guiding towards high end of range *New*

Adjusted EPS

$5.09-$5.59

Guiding to high end of range *New*

Free Cash Flow

>$600 Million *New*

Includes 2022 projected CAPEX of ~$400 million

Cash to Shareholders

The majority of our FCF

New $750 million share repurchase authorization thru 2025

Returned $350 million to shareholders as of June 30, 2022

Key Factors and Assumptions in Outlook *New*

- Continued demand strength in APM
- Pre-COVID seasonal patterns across the portfolio
- Continued normalization of supply chain and logistics
- TT ore constraints through Q4

See reconciliation of Non-GAAP measures in the Appendix

[1] Subject to risks, uncertainties and assumptions, all of which are described in our public filings and safe harbor statement

Chemours™

Our Priorities for Creating Shareholder Value

Improve TT earnings through the cycle while growing with strategic customers

Drive secular growth in TSS and APM behind class leading products and innovative chemistry

Continue to manage and resolve legacy liabilities consistent with Chemours/DD/CTVA MOU

Return the majority of the Free Cash Flow we generate to our shareholders

Chemours™

Segment Net Sales and Adjusted EBITDA (Unaudited)

($ in millions)	Three Months Ended June 30, 2022	Three Months Ended June 30, 2021	Three Months Ended March 31, 2022
SEGMENT NET SALES			
Titanium Technologies	$ 968	$ 859	$ 928
Thermal & Specialized Solutions	518	340	425
Advanced Performance Materials	401	362	385
Other Segment	28	94	26
Total Company	$ 1,915	$ 1,655	$ 1,764
SEGMENT ADJUSTED EBITDA			
Titanium Technologies	$ 216	$ 217	$ 206
Thermal & Specialized Solutions	213	115	174
Advanced Performance Materials	107	79	88
Other Segment	(2)	18	—
Corporate and Other	(59)	(63)	(65)
Total Company	$ 475	$ 366	$ 403
SEGMENT ADJUSTED EBITDA MARGIN			
Titanium Technologies	22%	25%	22%
Thermal & Specialized Solutions	41%	34%	41%
Advanced Performance Materials	27%	22%	23%
Other Segment	(7)%	19%	0%
Corporate and Other	—	—	—
Total Company	25%	22%	23%

Chemours™

GAAP Net Income Attributable to Chemours to Adjusted Net Income, Adjusted EBITDA, and Adjusted EPS Reconciliations (Unaudited)

($ in millions except per share amounts)	Three Months Ended June 30, 2022		2021		Three Months Ended March 31, 2022	
	$ amounts	$ per share*	$ amounts	$ per share*	$ amounts	$ per share*
Net income attributable to Chemours	$ 201	$ 1.26	$ 66	$ 0.39	$ 234	$ 1.43
Non-operating pension and other post-retirement employee benefit income	(2)	(0.01)	(2)	(0.01)	(1)	(0.01)
Exchange losses (gains), net	3	0.02	(3)	(0.02)	—	—
Restructuring, asset-related, and other charges	—	—	5	0.03	16	0.10
Gain on sales of assets and businesses, net	(26)	(0.16)	(2)	(0.01)	(1)	(0.01)
Natural disasters and catastrophic events	—	—	3	0.02	—	—
Transaction costs	—	—	—	—	—	—
Qualified spend recovery	(13)	(0.08)	—	—	(14)	(0.09)
Legal and environmental charges	170	1.06	195	1.15	8	0.05
Adjustments made to income taxes	(29)	(0.18)	(10)	(0.06)	(3)	(0.02)
Benefit from income taxes relating to reconciling items	(2)	(0.01)	(47)	(0.28)	—	—
Adjusted Net Income	$ 302	$ 1.89	$ 205	$ 1.20	$ 239	$ 1.46
Interest expense, net	40		47		41	
Depreciation and amortization	72		79		74	
All remaining provision for income taxes	61		35		49	
Adjusted EBITDA	$ 475		$ 366		$ 403	
Weighted-average number of common shares outstanding - basic	156,224,802		166,168,550		159,897,673	
Weighted-average number of common shares outstanding - diluted	159,667,213		170,158,003		163,579,580	
Basic earnings per share of common stock	$ 1.29		$ 0.40		$ 1.46	
Diluted earnings per share of common stock	1.26		0.39		1.43	
Adjusted basic earnings per share of common stock	1.93		1.23		1.49	
Adjusted diluted earnings per share of common stock	1.89		1.20		1.46	

Chemours™

Free Cash Flow Reconciliations (Unaudited)

($ in millions)	Three Months Ended			Six Months Ended	
	June 30,		March 31,	June 30,	
	2022	2021	2022	2022	2021
Cash flows provided by operating activities	$ 291	$ 256	$ 2	$ 293	$ 295
Less: Purchases of property, plant, and equipment	(62)	(67)	(106)	(168)	(127)
Free Cash Flows	$ 229	$ 189	$ (104)	$ 125	$ 168

Chemours™

Net Leverage Ratio (Unaudited)

($ in millions)	As of June 30, 2022	As of June 30, 2021
Total debt principal	$ 3,710	$ 4,020
Less: Cash and cash equivalents	(1,248)	(1,139)
Total debt principal, net	$ 2,462	$ 2,881

($ in millions)	Twelve Months Ended June 30, 2022	Twelve Months Ended June 30, 2021
Adjusted EBITDA (1)	$ 1,557	$ 1,090
Net Leverage Ratio	1.6x	2.6x

(1) Reconciliations of net income (loss) attributable to Chemours to Adjusted EBITDA are provided on a quarterly basis. See the preceding table for the reconciliation of net income (loss) attributable to Chemours to Adjusted EBITDA.

Return on Invested Capital (ROIC) (Unaudited)

($ in millions)	Twelve Months Ended June 30, 2022	Twelve Months Ended June 30, 2021
Adjusted EBITDA (1)	$ 1,557	$ 1,090
Less: Depreciation and amortization	(300)	(321)
Adjusted EBIT	$ 1,257	$ 769

($ in millions)	As of June 30, 2022	As of June 30, 2021
Total debt, net (2)	$ 3,680	$ 3,989
Total equity	1,215	900
Less: Cash and cash equivalents	(1,248)	(1,139)
Invested capital, net	$ 3,647	$ 3,750
Average invested capital (3)	$ 3,667	$ 3,834
Return on Invested Capital	34%	20%

(1) Reconciliations of net income (loss) attributable to Chemours to Adjusted EBITDA are provided on a quarterly basis. See the preceeding table for the reconciliation of net income (loss) attributable to Chemours to Adjusted EBITDA.

(2) Total debt principal minus unamortized issue discounts of $5 and $6 and debt issuance costs of $25 and $25 at June 30, 2022 and 2021, respectively

(3) Average invested capital is based on a five-quarter trailing average of invested capital, net.

Estimated GAAP Net Income Attributable to Chemours to Adjusted Net Income, Adjusted EBITDA and Adjusted EPS Reconciliation (*) (Unaudited)

(In millions except per share amounts)	(Estimated) Year Ended December 31, 2022 Low	(Estimated) Year Ended December 31, 2022 High
Net income attributable to Chemours	$ 712	$ 792
Restructuring, transaction, and other costs, net (1)	103	103
Adjusted Net Income	815	895
Interest expense, net	170	170
Depreciation and amortization	300	300
All remaining provision for income taxes	190	210
Adjusted EBITDA	$ 1,475	$ 1,575
Weighted-average number of common shares outstanding - basic (2)	156.6	156.6
Dilutive effect of the Company's employee compensation plans (3)	3.5	3.5
Weighted-average number of common shares outstanding - diluted	160.1	160.1
Basic earnings per share of common stock	$ 4.55	$ 5.06
Diluted earnings per share of common stock (4)	4.45	4.95
Adjusted basic earnings per share of common stock	5.20	5.72
Adjusted diluted earnings per share of common stock (4)	5.09	5.59

(1) Restructuring, transaction, and other costs, net includes the net provision for (benefit from) income taxes relating to reconciling items and adjustments made to income taxes for the removal of certain discrete income tax impacts.

(2) The Company's estimates for the weighted-average number of common shares outstanding - basic reflect results for the six months ended June 30, 2022, which are carried forward for the projection period.

(3) The Company's estimates for the dilutive effect of the Company's employee compensation plans reflect the dilutive effect for the six months ended June 30, 2022, which is carried forward for the projection period.

(4) Diluted earnings per share is calculated using net income available to common shareholders divided by diluted weighted-average common shares outstanding during each period, which includes unvested restricted shares. Diluted earnings per share considers the impact of potentially dilutive securities except in periods in which there is a loss because the inclusion of the potential common shares would have an anti-dilutive effect.

*The Company's estimates reflect its current visibility and expectations based on market factors, such as currency movements, macro-economic factors, and end-market demand. Actual results could differ materially from these current estimates.

Estimated GAAP Cash Flows Provided by Operating Activities to Free Cash Flow Reconciliations (Unaudited)

($ in millions)	(Estimated) Year Ended December 31, 2022	
Cash provided by operating activities	$	>1,000
Less: Purchases of property, plant, and equipment		~(400)
Free Cash Flows	$	>600

The Company's estimates reflect its current visibility and expectations based on market factors, such as currency movements, macro-economic factors, and end-market demand. Actual results could differ materially from these current estimates.

Chemours™